Repligen Corporation
RGEN · NASDAQ Global Select · USD
178,94USD
+5,45 (+3,14 %)Stand 9. Nov., 21:00
Vorbörslich180,13+1,19 (+0,67 %)7:18 ET
Kennzahlen
- Eröffnung
- 174,29
- Vortag
- 173,49
- Tagesspanne
- 173,72 – 181,02
- 52 Wochen
- 100,99 – 198,87
- Volumen
- 1,1 Mio.
- Ø Volumen
- 1,19 Mio.
- Börsenwert
- 11,44 Mrd. $
- KGV
- -852,1
- Gewinn je Aktie (TTM)
- -0,21
- Dividendenrendite
- 0,0 %
- Beta
- 1,1
- Nächste Zahlen
- 23. Feb. 2027
Finanzen
| USD | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Umsatz | 738,26 Mio. | 634,44 Mio. | 632,36 Mio. | 801,54 Mio. | 670,53 Mio. |
| Herstellungskosten | 390,63 Mio. | 359,79 Mio. | 353,92 Mio. | 345,83 Mio. | 279,28 Mio. |
| Bruttogewinn | 347,62 Mio. | 274,65 Mio. | 278,44 Mio. | 455,71 Mio. | 391,25 Mio. |
| Forschung und Entwicklung | 54,18 Mio. | 43,2 Mio. | 42,72 Mio. | 43,94 Mio. | 34,27 Mio. |
| Vertrieb und Verwaltung | 290,51 Mio. | 263,37 Mio. | 218,58 Mio. | 215,83 Mio. | 183,87 Mio. |
| Operatives Ergebnis | 59,58 Mio. | −35,11 Mio. | 47,7 Mio. | 224,67 Mio. | 167,25 Mio. |
| EBITDA | 182,51 Mio. | 80,26 Mio. | 145,32 Mio. | 277,31 Mio. | 203,27 Mio. |
| Nettogewinn | 48,89 Mio. | −25,51 Mio. | 35,6 Mio. | 185,96 Mio. | 128,29 Mio. |
| Gewinn je Aktie (verwässert) | 0,86 | -0,46 | 0,63 | 3,24 | 2,24 |
Umsatz nach Segment
Produkte · FY 2025
- Product737,96 Mio. $50,00 %+16,36 %
- Filtration Products402,79 Mio. $27,29 %+8,00 %
- Chromatography Products153,18 Mio. $10,38 %+24,73 %
- Proteins Products97,44 Mio. $6,60 %+30,92 %
- Process Analytics Products81,24 Mio. $5,50 %+36,99 %
- Other products3,32 Mio. $0,22 %−29,04 %
Anteil · ggü. Vorjahr (FY 2024)
Bewertung
Letzte 12 Monate
- KGV
- -852,1
- Kurs-Umsatz-Verhältnis
- 14,2
- Kurs-Buchwert-Verhältnis
- 4,8
- PEG
- 1,1
- Bruttomarge
- 51,1 %
- Operative Marge
- 2,3 %
- Nettomarge
- −1,5 %
- Verschuldungsgrad
- 0,3
- EV/EBITDA
- 90,6
- Eigenkapitalrendite
- −0,6 %
- Kapitalrendite (ROIC)
- −1,0 %
- Free-Cashflow-Rendite
- 0,9 %
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | |
|---|---|---|---|---|---|
| Bruttomarge | 47,1 % | 43,3 % | 44,0 % | 56,9 % | 58,3 % |
| Operative Marge | 8,1 % | −5,5 % | 7,5 % | 28,0 % | 24,9 % |
| Nettomarge | 6,6 % | −4,0 % | 5,6 % | 23,2 % | 19,1 % |
| KGV | 188,3 | -312,9 | 280,9 | 50,5 | 113,7 |
| Kurs-Umsatz-Verhältnis | 12,5 | 12,7 | 15,8 | 11,7 | 21,7 |
| Kurs-Buchwert-Verhältnis | 4,4 | 4,1 | 5,1 | 4,9 | 8,3 |
| Verschuldungsgrad | 0,3 | 0,3 | 0,4 | 0,2 | 0,2 |
| Liquidität 3. Grades | 8,4 | 8,4 | 6,7 | 2,5 | 2,5 |
| Dividendenrendite | 0,0 % | 0,0 % | 0,0 % | 0,0 % | 0,0 % |
| Unternehmenswert | 9,34 Mrd. | 7,98 Mrd. | 9,98 Mrd. | 9,29 Mrd. | 14,33 Mrd. |
| EV/EBITDA | 51,2 | 99,4 | 68,7 | 33,5 | 70,5 |
| Eigenkapitalrendite | 2,3 % | −1,3 % | 1,8 % | 9,7 % | 7,3 % |
| Kapitalrendite (ROIC) | 1,6 % | −1,2 % | 1,1 % | 7,9 % | 6,2 % |
| Free-Cashflow-Rendite | 1,0 % | 1,8 % | 0,7 % | 0,4 % | 0,4 % |
Wachstum
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | |
|---|---|---|---|---|---|
| Umsatz | +16,4 % | +0,3 % | −21,1 % | +19,5 % | +83,1 % |
| Bruttogewinn | +26,6 % | −1,4 % | −38,9 % | +16,5 % | +101,3 % |
| Operatives Ergebnis | +269,7 % | −173,6 % | −78,8 % | +34,3 % | +105,7 % |
| Nettogewinn | +291,6 % | −171,7 % | −80,9 % | +45,0 % | +114,1 % |
| Gewinn je Aktie | +287,0 % | −173,0 % | −80,6 % | +44,6 % | +101,8 % |
| Freier Cashflow | −34,1 % | +90,2 % | +93,4 % | −25,4 % | +43,1 % |
| Dividende je Aktie | 0,0 % | 0,0 % | 0,0 % | 0,0 % | 0,0 % |
Analysten
Einstufungen · Buy
- 1Stark kaufen
- 21Kaufen
- 2Halten
- 0Verkaufen
- 0Stark verkaufen
Kursziel
198,00
Durchschnitt · +10,65 %
Schätzungen
| FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|
| Umsatz (Ø) | 848,89 Mio. | 1,07 Mrd. | 1,23 Mrd. |
| Umsatz (Tief – Hoch) | 828,45 Mio. – 858,02 Mio. | 1,06 Mrd. – 1,08 Mrd. | 1,2 Mrd. – 1,31 Mrd. |
| Gewinn je Aktie (Ø) | 2,07 | 2,66 | 3,42 |
| Gewinn je Aktie (Tief – Hoch) | 2,05 – 2,09 | 2,48 – 2,78 | 0,56 – 4,41 |
| Analysten | 11 | 9 | 7 |
Letzte Änderungen
- RBC Capital28. Okt. 2026Outperform
- Canaccord Genuity19. Okt. 2026Hold
- Barclays7. Okt. 2026Overweight
- UBS9. Sept. 2026Buy
- Wells Fargo30. Juli 2026Overweight
- JP Morgan29. Juli 2026Overweight
- Benchmark7. Juli 2026Hold → Buy
- Evercore ISI Group6. Juli 2026Outperform
Quartalszahlen
Nächste Zahlen: 23. Feb. 2027| Okt. 2026 | Juli 2026 | Mai 2026 | Feb. 2026 | Okt. 2025 | Juli 2025 | Apr. 2025 | Feb. 2025 | |
|---|---|---|---|---|---|---|---|---|
| Gewinn je Aktie · Erwartet | 0,46 | 0,45 | 0,38 | 0,44 | 0,42 | 0,40 | 0,35 | 0,41 |
| Gewinn je Aktie · Tatsächlich | 0,53 | 0,54 | 0,48 | 0,49 | 0,46 | 0,37 | 0,39 | 0,44 |
| Abweichung | +14,52 % | +20,81 % | +26,32 % | +11,36 % | +9,52 % | −7,50 % | +11,43 % | +7,32 % |
| Umsatz · Tatsächlich | 209,31 Mio. | 204,13 Mio. | 194,26 Mio. | 197,91 Mio. | 188,81 Mio. | 182,37 Mio. | 169,17 Mio. | 167,55 Mio. |
Dividenden und Splits
Keine Dividenden gezahlt.
Aktiensplits
–
Eigentümer
Institutionen
Q2 2026 · 13F
- Anteil institutioneller Investoren
- 118,06 %
- Investoren mit 13F-Meldung
- 500
Größte Investoren
- BLACKROCK, INC.9,55 %5,38 Mio.
- FMR LLC5,90 %3,33 Mio.
- UNITED CAPITAL FINANCIAL ADVISORS, LLC4,95 %2,79 Mio.
- VANGUARD CAPITAL MANAGEMENT LLC4,28 %2,41 Mio.
- VANGUARD PORTFOLIO MANAGEMENT LLC4,10 %2,31 Mio.
- MAVERICK CAPITAL LTD3,52 %1,98 Mio.
- STATE STREET CORP3,20 %1,8 Mio.
- PRICE T ROWE ASSOCIATES INC /MD/3,11 %1,75 Mio.
Insider-Geschäfte
- Douglass Brian Robb6. Okt. 2026 · officer: CHIEF PRODUCT OFFICERKauf700 Aktien
- Douglass Brian Robb6. Okt. 2026 · officer: CHIEF PRODUCT OFFICERKauf675 Aktien · 174,86
- Loeillot Olivier5. Okt. 2026 · director, officer: Chief Executive OfficerKauf4202 Aktien · 154,96
- Loeillot Olivier5. Okt. 2026 · director, officer: Chief Executive OfficerVerkauf1333 Aktien · 178,75
- Loeillot Olivier5. Okt. 2026 · director, officer: Chief Executive OfficerVerkauf4202 Aktien · 190,00
- Loeillot Olivier5. Okt. 2026 · director, officer: Chief Executive OfficerVerkauf4202 Aktien · 154,96
- Loeillot Olivier2. Okt. 2026 · director, officer: Chief Executive OfficerVerkauf1248 Aktien · 181,70
- Garland Jason K25. Sept. 2026 · officer: CFOVerkauf421 Aktien · 189,68
Vergleichbare Unternehmen
AAgilent Technologies, Inc.180,17+3,10 %
AVTRAvantor, Inc.15,91+2,84 %
BIOBio-Rad Laboratories, Inc.388,31+1,77 %
BLFSBioLife Solutions, Inc.38,610,00 %
MRVIMaravai LifeSciences Holdings, Inc.8,02+6,65 %
QGENQiagen N.V.50,55+0,44 %
SDMHFSartorius Stedim Biotech S.A.252,04+1,63 %
SOAGYSartorius AG ADR66,15+2,08 %
Über das Unternehmen
Repligen Corporation specializes in the creation and distribution of advanced bioprocessing technologies and integrated systems. These solutions are vital for various stages of biological drug production, serving clients across North America, Europe, the Asia Pacific region, and other international markets. The company's diverse product portfolio includes crucial components for biomanufacturing. This encompasses Protein A ligands, which serve as the key binding elements within Protein A affinity chromatography resins, as well as specialized cell culture growth factors. In the realm of chromatography, Repligen offers a range of products: Its OPUS line features pre-packed chromatography columns, instrumental in purifying biologics, alongside smaller-scale OPUS columns designed for high-throughput process development screening, viral clearance validation studies, and the scaling-down of chromatography processes. Additionally, the company supplies ELISA test kits and chromatography resins marketed under the CaptivA brand. Repligen also boasts an extensive suite of filtration products. This includes XCell Alternating Tangential Flow systems, which are filtration devices utilized in upstream perfusion and cell culture processing. For downstream applications like biologic drug concentration and formulation, they provide TangenX flat sheet cassettes. Other filtration offerings encompass KrosFlo tangential flow filtration and tangential flow depth filtration systems, Spectra/Por laboratory and process dialysis products, SpectraFlo dynamic dialysis systems, and ProConnex single-use hollow fibers. Furthermore, Repligen addresses process analytics with its slope spectroscopy systems, branded as SoloVPE, FlowVPE, and FlowVPX. Their clientele is broad, consisting of life sciences organizations, biopharmaceutical and diagnostics companies, laboratory researchers, and contract manufacturing organizations. Repligen also collaborates with partners, such as Navigo Proteins GmbH, on the development of various affinity ligands. The corporation was founded in 1981 and maintains its corporate headquarters in Waltham, Massachusetts.
Führung
- Olivier LoeillotPresident, Chief Executive Officer & Director
- Jason K. GarlandChief Financial Officer & Chief Compliance Officer
- James R. BylundChief Operating Officer
- Ralf KuriyelSenior Vice President of Research & Development
- Anthony J. HuntAdvisor
- Brian DouglassSenior VP & Chief Product Officer
- CEO
- Olivier Loeillot
- Mitarbeitende
- 2.000
- Hauptsitz
- Waltham, MA, US
- Sektor
- Healthcare
- Branche
- Medical - Instruments & Supplies
- Börsengang
- 29. Apr. 1986
- Website
- repligen.com
Nachrichten
- The Motley Fool · 5. Nov., 11:30Repligen: 3 Key Takeaways for Long-Term Investors
- GlobeNewsWire · 4. Nov., 7:00Repligen Corporation to Present at Jefferies Global Healthcare Conference
- Seeking Alpha · 3. Nov., 8:10Baron SMID Cap ETF Q3 2026 Contributors And Detractors
- GlobeNewsWire · 30. Okt., 6:00Repligen Announces $1 Billion Private Convertible Senior Notes Transaction
- Seeking Alpha · 29. Okt., 20:50Conestoga Micro Cap Composite: Q3 2026 Leaders, Laggards, Buys And Sells
- Seeking Alpha · 27. Okt., 14:50Repligen Corporation (RGEN) Q3 2026 Earnings Call Transcript
- MarketBeat · 27. Okt., 11:07What Repligen (RGEN) Said on Its Q3 Earnings Call
- Seeking Alpha · 27. Okt., 10:35Conestoga Small Cap Composite Q3 2026 Portfolio Activity
- Zacks Investment Research · 27. Okt., 9:16Repligen (RGEN) Q3 Earnings and Revenues Surpass Estimates
- GlobeNewsWire · 27. Okt., 7:00Repligen Reports Third Quarter 2026 Financial Results and Updates Full Year 2026 Financial Guidance
Kurse mindestens 15 Minuten verzögert. Daten: Financial Modeling Prep. Keine Anlageberatung.